Copyright Reports & Markets. All rights reserved.

Defibrillator Devices Global Market

Request for Sample of this report
Buy now

1 EXECUTIVE SUMMARY 22

    2 INTRODUCTION 30

    • 2.1 KEY TAKE AWAYS 30
    • 2.2 REPORT DESCRIPTION 31
    • 2.3 MARKETS COVERED 32
    • 2.4 STAKEHOLDERS 34
    • 2.5 RESEARCH METHODOLOGY 35
      • 2.5.1 MARKET SIZE ESTIMATION 36
      • 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 39
      • 2.5.3 SECONDARY SOURCES 40
      • 2.5.4 PRIMARY SOURCES 40
      • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 41
      • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 42
      • 2.5.7 ASSUMPTIONS 42

    3 MARKET ANALYSIS 44

    • 3.1 INTRODUCTION 44
    • 3.2 MARKET SEGMENTATION 45
    • 3.3 FACTORS INFLUENCING MARKET 47
      • 3.3.1 DRIVERS AND OPPORTUNITIES 48
        • 3.3.1.1 Increase in aging population and subsequent rise in incidence of cardiovascular diseases 48
        • 3.3.1.2 Increasing use of defibrillators in public access areas 48
        • 3.3.1.3 Favorable reimbursement policies 49
        • 3.3.1.4 Emergence of next generation integrated ICD’s 50
        • 3.3.1.5 Increasing trend for MRI compatible defibrillators 51
        • 3.3.1.6 Market expansion opportunities in emerging nations 51
      • 3.3.2 RESTRAINTS AND THREATS 52
        • 3.3.2.1 Patient safety risks due to chances of infections and other complications while using defibrillators 52
        • 3.3.2.2 Lack of awareness on sudden cardiac arrests 53
        • 3.3.2.3 Lack of cybersecurity in ICD’s 53
        • 3.3.2.4 Increasing number of defibrillator devices product recalls due to FDA mandates 54
    • 3.4 REIMBURSEMENT SCENARIO 55
      • 3.4.1 REIMBURSEMENT TABLE 55
    • 3.5 REGULATORY AFFAIRS 58
      • 3.5.1 U.S. 58
      • 3.5.2 EUROPE 59
      • 3.5.3 INDIA 59
      • 3.5.4 CHINA 60
      • 3.5.5 JAPAN 60
    • 3.6 TECHNOLOGICAL ADVANCEMENTS AND ON GOING CLINICAL TRIALS 61
      • 3.6.1 NEXT GENERATION ICD’s 61
      • 3.6.2 CUSTOMIZED DEFIBRILLATOR DEVICES & CONSUMABLES 62
      • 3.6.3 LEADLESS DEFIBRILLATORS 62
      • 3.6.4 3D PRINTED MULTIFUNCTIONAL INTEGUMENTARY MEMBRANE DEVICES

    (MIM) FOR ARRYTHMIAS DIAGNOSIS 63

    • 3.6.5 AMBULANCE DRONE 64
    • 3.6.6 AMBULANCE ROBOTIC ASSISTED AED’s IN SMART CITIES 64
    • 3.6.7 DEFIBRILLATOR DEVICES UNDER CLINICAL TRIAL 65
  • 3.7 MODE OF OPERATION 70
    • 3.7.1 EXTERNAL MODE OF OPERATION 71
    • 3.7.2 INTERNAL MODE OF OPERATION 72
    • 3.7.3 SYNCHRONIZED MODE OF OPERATION 74
  • 3.8 PATENT ANALYSIS 75
  • 3.9 SUPPLY CHAIN ANALYSIS 76
  • 3.10 PORTER’S FIVE FORCE ANALYSIS 81
    • 3.10.1 THREAT OF NEW ENTRANTS 83
    • 3.10.2 THREAT OF SUBSTITUTES 83
    • 3.10.3 RIVALRY AMONG EXISTING COMPETITORS 84
    • 3.10.4 BARGAINING POWER OF SUPPLIERS 85
    • 3.10.5 BARGAINING POWER OF BUYERS 85
  • 3.11 IMPLANTABLE CARDIOVERTER DEFIBRILLATOR V/S EXTERNAL DEFIBRILLATOR

    • DEVICES 86

    • 3.12 MARKET SHARE ANALYSIS 88
      • 3.12.1 DEFIBRILLATOR DEVICES GLOBAL MARKET SHARE ANALYSIS 88
      • 3.12.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATOR GLOBAL MARKET SHARE

    ANALYSIS 91

    • 3.12.3 AUTOMATED EXTERNAL DEFIBRILLATORS GLOBAL MARKET SHARE

    ANALYSIS 93

    • 3.12.4 ADVANCED LIFE SUPPORT (ALS) DEFIBRILLATORS GLOBAL MARKET

    SHARE ANALYSIS 95

      4 DEFIBRILLATOR DEVICES GLOBAL MARKET, BY PRODUCTS 97

      • 4.1 INTRODUCTION 97
      • 4.2 DEVICES 101
        • 4.2.1 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD’S) 106
          • 4.2.1.1 Transvenous Implantable Cardioverter Defibrillators (T-ICD’s) 113
          • 4.2.1.1.1 Biventricular ICD’s/Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) ………………………………………………………………………………………………………………………… 116
          • 4.2.1.1.2 Dual Chamber ICD’s 120
          • 4.2.1.1.3 Single Chamber ICD’s 123
          • 4.2.1.2 Subcutaneous Implantable Cardioverter Defibrillators (S-ICD’s) 126
        • 4.2.2 EXTERNAL DEFIBRILLATORS 129
          • 4.2.2.1 Automated External Defibrillators (AEDs) 134
          • 4.2.2.1.1 Semi-Automated AEDs 142
          • 4.2.2.1.2 Fully Automated AED’s 144
          • 4.2.2.2 Wearable Cardioverter Defibrillators (WCD)/ Wearable External Defibrillators (WED) 146
          • 4.2.2.3 Advanced Life Support Defibrillators (ALS) 149
      • 4.3 CONSUMABLES 154
      • 4.4 SERVICING 163

      5 DEFIBRILLATOR DEVICES GLOBAL MARKET, BY APPLICATIONS 166

      • 5.1 INTRODUCTION 166
      • 5.2 VENTRICULAR TACHYCARDIA 169
      • 5.3 VENTRICULAR FIBRILLATION 171
      • 5.4 BRADYCARDIA 174

      6 DEFIBRILLATOR DEVICES GLOBAL MARKET, BY END-USERS 176

      • 6.1 INTRODUCTION 176
      • 6.2 HOSPITALS 178
      • 6.3 HOME HEALTHCARE PROVIDERS 180
      • 6.4 AMBULATORY SURGICAL CENTERS 182
      • 6.5 PUBLIC ACCESS CARE 184
      • 6.6 PRE-HOSPITAL CARE 186
      • 6.7 OTHERS 187

      7 DEFIBRILLATOR DEVICES GLOBAL MARKET, BY GEOGRAPHY 190

      • 7.1 INTRODUCTION 190
      • 7.2 NORTH AMERICA 191
        • 7.2.1 UNITED STATES (U.S.) 203
        • 7.2.2 OTHERS 206
      • 7.3 EUROPE 210
        • 7.3.1 FRANCE 222
        • 7.3.2 ITALY 225
        • 7.3.3 GERMANY 228
        • 7.3.4 OTHERS 230
      • 7.4 ASIA-PACIFIC (APAC) 234
        • 7.4.1 INDIA 245
        • 7.4.2 CHINA 248
        • 7.4.3 JAPAN 251
        • 7.4.4 OTHERS 254
      • 7.5 REST OF WORLD (ROW) 258
        • 7.5.1 BRAZIL 269
        • 7.5.2 REST OF LATIN AMERICA 271
        • 7.5.3 MIDDLE EAST & OTHERS 273

      8 COMPANY DEVELOPMENTS 276

      • 8.1 INTRODUCTION 276
        • 8.1.1 APPROVAL AS A MAJOR GROWTH STRATEGY OF DEFIBRILLATOR DEVICES

      PLAYERS 276

      • 8.2 APPROVALS 278
      • 8.3 NEW PRODUCT LAUNCH 285
      • 8.4 OTHER DEVELOPMENTS 290
      • 8.5 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 292
      • 8.6 MERGERS & ACQUISITIONS 293

      9 COMPANY PROFILES 295

      • 9.1 ABBOTT LABORATORIES, INC (ST JUDE MEDICAL, INC.) 295
        • 9.1.1 OVERVIEW 295
        • 9.1.2 FINANCIALS 296
        • 9.1.3 PRODUCT PORTFOLIO 298
        • 9.1.4 KEY DEVELOPMENTS 300
        • 9.1.5 BUSINESS STRATEGY 302
        • 9.1.6 SWOT ANALYSIS 303
      • 9.2 ASAHI KASEI CORPORATION (ZOLL MEDICAL CORPORATION) 304
        • 9.2.1 OVERVIEW 304
        • 9.2.2 FINANCIALS 305
        • 9.2.3 PRODUCT PORTFOLIO 308
        • 9.2.4 KEY DEVELOPMENTS 309
        • 9.2.5 BUSINESS STRATEGY 310
        • 9.2.6 SWOT ANALYSIS 311
      • 9.3 AURORA CAPITAL GROUP (CARDIAC SCIENCE CORPORATION) 312
        • 9.3.1 OVERVIEW 312
        • 9.3.2 FINANCIALS 312
        • 9.3.3 PRODUCT PORTFOLIO 313
        • 9.3.4 KEY DEVELOPMENTS 314
        • 9.3.5 BUSINESS STRATEGY 315
        • 9.3.6 SWOT ANALYSIS 316
      • 9.4 BOSTON SCIENTIFIC CORPORATION 317
        • 9.4.1 OVERVIEW 317
        • 9.4.2 FINANCIALS 318
        • 9.4.3 PRODUCT PORTFOLIO 321
        • 9.4.4 KEY DEVELOPMENTS 322
        • 9.4.5 BUSINESS STRATEGY 324
        • 9.4.6 SWOT ANALYSIS 325
      • 9.5 BIOTRONIK SE & CO.KG 326
        • 9.5.1 OVERVIEW 326
        • 9.5.2 FINANCIALS 326
        • 9.5.3 PRODUCT PORTFOLIO 327
        • 9.5.4 KEY DEVELOPMENTS 327
        • 9.5.5 BUSINESS STRATEGY 331
        • 9.5.6 SWOT ANALYSIS 332
      • 9.6 LIVANOVA (SORIN GROUP) 333
        • 9.6.1 OVERVIEW 333
        • 9.6.2 FINANCIALS 334
        • 9.6.3 PRODUCT PORTFOLIO 337
        • 9.6.4 KEY DEVELOPMENTS 337
        • 9.6.5 BUSINESS STRATEGY 338
        • 9.6.6 SWOT ANALYSIS 339
      • 9.7 MEDTRONIC PLC 340
        • 9.7.1 OVERVIEW 340
        • 9.7.2 FINANCIALS 341
        • 9.7.3 PRODUCT PORTFOLIO 345
        • 9.7.4 KEY DEVELOPMENTS 346
        • 9.7.5 BUSINESS STRATEGY 348
        • 9.7.6 SWOT ANALYSIS 349
      • 9.8 NIHON KOHDEN CORPORATION 350
        • 9.8.1 OVERVIEW 350
        • 9.8.2 FINANCIALS 351
        • 9.8.3 PRODUCT PORTFOLIO 354
        • 9.8.4 KEY DEVELOPMENTS 355
        • 9.8.5 BUSINESS STRATEGY 356
        • 9.8.6 SWOT ANALYSIS 357
      • 9.9 PHILIPS HEALTHCARE 358
        • 9.9.1 OVERVIEW 358
        • 9.9.2 FINANCIALS 359
        • 9.9.3 PRODUCT PORTFOLIO 362
        • 9.9.4 KEY DEVELOPMENTS 362
        • 9.9.5 BUSINESS STRATEGY 363
        • 9.9.6 SWOT ANALYSIS 364
      • 9.10 STRYKER CORPORATION 365
        • 9.10.1 OVERVIEW 365
        • 9.10.2 FINANCIALS 366
        • 9.10.3 PRODUCT PORTFOLIO 369
        • 9.10.4 KEY DEVELOPMENTS 370
        • 9.10.5 BUSINESS STRATEGY 371

      Defibrillator devices are class of medical devices used for delivering shock in a controlled and automated manner. These devices are mainly used for therapeutic purposes in cardiovascular critical care management, where electrical shock is required to convert patient’s abnormal heart rhythm into normal heart rhythm to revive the victim of sudden cardiac arrest. These defibrillators help in saving the life of a SCA victim, who would have few minutes lifeline and requires resuscitation to avoid situations, which would lead to serious life threatening circumstances or even sometimes to death of a patient.
      Defibrillator devices market is segmented on the basis of products, applications, end-users and geography. Products are segmented into devices, consumables and servicing, whereas devices are further segmented into Implantable Cardioverter Defibrillators (ICD’s) and external defibrillators. Implantable cardioverter defibrillators are further segmented into Transvenous Implantable Cardioverter Defibrillators (T-ICD’s) and Subcutaneous Implantable Cardioverter Defibrillators (S-ICD’s), similarly external defibrillators are classified into Automated External Defibrillators (AED’s), Wearable cardioverter defibrillators and Advanced Life Support Defibrillators (ALS). Consumables are further segmented into electrode pads, battery & chargers, first aid kits and supplies/rescue kits and others including cables & data cables, carry cases or backpacks, training units, training manikins and cabinets Applications are segmented into ventricular fibrillation, ventricular tachycardia and bradycardia. End-users are further classified into hospitals, ambulatory surgical centers, homecare, public access care, pre-hospitals and others (clinics & cardiac centers & alternative care centers).
      According to IQ4I analysis, the defibrillator devices global market is expected to grow at a mid to high single digit CAGR to reach $17,710.8 million by 2023. Among the defibrillator devices products market implantable cardioverter defibrillators segment holds the largest share of the market and external defibrillators is expected to be the fastest growing segment. In applications market ventricular tachycardia holds the largest share of the market and ventricular fibrillation is expected to grow with a strong CAGR from 2016 to 2023. In end- users, hospitals are the largest segment and home healthcare is the fastest growing segment from 2016 to 2023. Geographically, North America is the largest market followed by Europe and Asia Pacific. The APAC region is the fastest growing region from 2016 to 2023 presenting an array of opportunities for growth and is likely to get attention of new investors in the defibrillator devices market. Growth in the Asian market is attributed to rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
      The defibrillator devices market is expected to grow at a single high digit CAGR during 2016 to 2023. Increase in aging population and subsequent rise in incidence of cardiovascular diseases, increasing use of defibrillators in public access areas and favorable reimbursement policies are the factors driving the market growth. Increasing trend of MRI compatible defibrillators, emergence of next generation integrated ICD’s and market expansion opportunities in emerging nations are expected to offer potential opportunities.
      However various factors like patient safety risks due to chances of infection and other complications while using defibrillators, lack of awareness on sudden cardiac arrests limit the growth of defibrillator devices global market. The threats for the defibrillator devices market include lack of cybersecurity in ICD’s and increasing number of defibrillator device recalls due to FDA mandates.
      The defibrillator devices global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the defibrillator devices market are Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), Asahi Kasei Corporation (Japan), Medtronic PLC (Ireland), Philips Healthcare (Netherland), Biotronik Se & Co. Kg (Germany), Stryker Corporation (U.S.), LivaNova (U.K.) and Nihon Kohden Corporation (Japan).
      The report provides an in depth market analysis of the above mentioned segments across the following regions:
      • North America
      • Europe
      • Asia-Pacific
      • Rest of the World (RoW)

      Buy now